RecruitingPhase 2NCT07203144

Selenium Supplementation for Improving Depression in Children and Adolescents: Efficacy and Mechanistic Study

Sponsor

First Affiliated Hospital of Chongqing Medical University

Enrollment

172 participants

Start Date

Dec 31, 2025

Study Type

INTERVENTIONAL

Conditions

Depression - Major Depressive Disorder

Summary

The purpose of this study is to investigate the role and mechanisms of selenium in depression among children and adolescents, aiming to provide new insights for understanding the pathogenesis and treatment of depression in this population.

Eligibility

Min Age: 12 YearsMax Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo yeast supplementation and a drug called selenium yeast supplementation for people with depression - major depressive disorder. The study is currently recruiting participants at 1 location. People eligible for this study include aged 12 Years to 18 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGselenium yeast supplementation

In this intervention, patients will receive adjunctive selenium yeast supplementation at a daily dose of 60-200 μg in addition to fluoxetine. Symptom rating scales, biospecimen collection, and brain MRI will be conducted at baseline, week 4, and week 8 to investigate the adjunctive role of selenium in fluoxetine treatment for depression.

DRUGPlacebo yeast supplementation

In this intervention, patients will receive standard fluoxetine treatment combined with placebo yeast supplementation (60-200 μg/day), which is identical in appearance and odor to selenium yeast. The aim is to clarify the specific role of selenium in the treatment of depression.